BNP Paribas Financial Markets’s Supernus Pharmaceuticals SUPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.91M Buy
148,579
+86,596
+140% +$4.16M ﹤0.01% 1870
2026
Q1
$3.2M Sell
61,983
-15,647
-20% -$797K ﹤0.01% 2353
2025
Q4
$3.86M Sell
77,630
-338,060
-81% -$16.4M ﹤0.01% 2212
2025
Q3
$19.9M Buy
415,690
+113,025
+37% +$4.55M 0.01% 1125
2025
Q2
$9.54M Buy
302,665
+42,604
+16% +$1.37M 0.01% 1478
2025
Q1
$8.52M Sell
260,061
-32,568
-11% -$1.15M 0.01% 1493
2024
Q4
$10.6M Buy
292,629
+208,552
+248% +$7.34M 0.01% 1329
2024
Q3
$2.62M Buy
84,077
+11,125
+15% +$347K ﹤0.01% 1897
2024
Q2
$1.95M Sell
72,952
-4,908
-6% -$142K ﹤0.01% 1933
2024
Q1
$2.66M Buy
77,860
+24,428
+46% +$727K ﹤0.01% 1874
2023
Q4
$1.55M Buy
53,432
+14,129
+36% +$375K ﹤0.01% 2122
2023
Q3
$1.08M Buy
39,303
+25,773
+190% +$785K ﹤0.01% 2281
2023
Q2
$407K Sell
13,530
-11,483
-46% -$402K ﹤0.01% 2693
2023
Q1
$906K Buy
25,013
+7,773
+45% +$299K ﹤0.01% 2386
2022
Q4
$615K Buy
+17,240
New +$599K ﹤0.01% 2455
2022
Q3
Sell
-23,262
Closed -$673K 5014
2022
Q2
$673K Buy
23,262
+5,921
+34% +$170K ﹤0.01% 2480
2022
Q1
$560K Sell
17,341
-43,179
-71% -$1.32M ﹤0.01% 2688
2021
Q4
$1.76M Buy
60,520
+5,940
+11% +$180K ﹤0.01% 2147
2021
Q3
$1.46M Buy
54,580
+30,627
+128% +$822K ﹤0.01% 2121
2021
Q2
$738K Buy
23,953
+1,040
+5% +$31.9K ﹤0.01% 2348
2021
Q1
$600K Buy
22,913
+6,813
+42% +$191K ﹤0.01% 2466
2020
Q4
$405K Buy
16,100
+2,398
+18% +$51.6K ﹤0.01% 2569
2020
Q3
$286K Sell
13,702
-13,100
-49% -$297K ﹤0.01% 2549
2020
Q2
$637K Sell
26,802
-99,054
-79% -$2.19M ﹤0.01% 1994
2020
Q1
$2.26M Buy
125,856
+113,357
+907% +$2.38M ﹤0.01% 1414
2019
Q4
$296K Buy
12,499
+3,555
+40% +$86.3K ﹤0.01% 2775
2019
Q3
$246K Buy
8,944
+2,367
+36% +$70.1K ﹤0.01% 2641
2019
Q2
$218K Sell
6,577
-4,768
-42% -$163K ﹤0.01% 2570
2019
Q1
$398K Buy
11,345
+10,176
+870% +$379K ﹤0.01% 2248
2018
Q4
$38.8K Sell
1,169
-2,532
-68% -$109K ﹤0.01% 2838
2018
Q3
$186K Sell
3,701
-4,569
-55% -$226K ﹤0.01% 2433
2018
Q2
$495K Sell
8,270
-11,388
-58% -$590K ﹤0.01% 2017
2018
Q1
$900K Sell
19,658
-1,006
-5% -$42K ﹤0.01% 1814
2017
Q4
$823K Sell
20,664
-5,408
-21% -$214K ﹤0.01% 2117
2017
Q3
$1.04M Buy
26,072
+11,038
+73% +$478K ﹤0.01% 1532
2017
Q2
$648K Sell
15,034
-123,726
-89% -$4.4M ﹤0.01% 1767
2017
Q1
$4.34M Buy
138,760
+128,598
+1,265% +$3.45M 0.01% 808
2016
Q4
$257K Buy
10,162
+3,304
+48% +$73.8K ﹤0.01% 2058
2016
Q3
$170K Sell
6,858
-4,620
-40% -$105K ﹤0.01% 1832
2016
Q2
$234K Buy
11,478
+6,407
+126% +$114K ﹤0.01% 1840
2016
Q1
$77.3K Sell
5,071
-2,083
-29% -$27.2K ﹤0.01% 1875
2015
Q4
$96.2K Sell
7,154
-673
-9% -$10.4K ﹤0.01% 2361
2015
Q3
$110K Buy
7,827
+4,969
+174% +$92.4K ﹤0.01% 2332
2015
Q2
$48.5K Buy
2,858
+2,177
+320% +$31K ﹤0.01% 2513
2015
Q1
$8.23K Buy
+681
New +$6.43K ﹤0.01% 2861
2014
Q4
Sell
-2,248
Closed -$19.5K 3040
2014
Q3
$19.5K Buy
+2,248
New +$20.3K ﹤0.01% 3180
2014
Q2
Sell
-62
Closed -$509 3938
2014
Q1
$509 Sell
62
-138
-69% -$1.27K ﹤0.01% 3039
2013
Q4
$1.51K Buy
+200
New +$1.4K ﹤0.01% 3763

Other funds holding SUPN

BNP Paribas Financial Markets's SUPN Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Supernus Pharmaceuticals (SUPN) stake by 140% in Q2 2026, buying an estimated $4.16M and bringing the position to 148,579 shares worth $6.91M. The position accounts for ﹤0.01% of the portfolio, ranked #1870.

BNP Paribas Financial Markets first reported a position in SUPN in Q4 2013 and has held it in 48 quarters since. The position peaked at $19.9M in Q3 2025. 311 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • BNP Paribas Financial Markets held 148,579 shares of Supernus Pharmaceuticals worth $6.91M as of Q2 2026.
  • BNP Paribas Financial Markets bought 86,596 Supernus Pharmaceuticals shares in Q2 2026, an estimated $4.16M.
  • Supernus Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #1870 holding.
  • BNP Paribas Financial Markets first reported a position in Supernus Pharmaceuticals in Q4 2013 and has held it in 48 quarters since.
  • BNP Paribas Financial Markets's Supernus Pharmaceuticals position peaked at $19.9M in Q3 2025.
  • 311 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.